ArticleCancer management and research2026
Development and Validation of a Clinical Radiomics Nomogram for Predicting Early Recurrence After Microwave Ablation in Hepatocellular Carcinoma Patients With Type 2 Diabetes.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and validate a non-invasive model for predicting early recurrence (ER) after microwave ablation (MWA) in patients with hepatocellular carcinoma (HCC) and comorbid type 2 diabetes (T2D). Methods: This retrospective study enrolled 186 HCC patients with T2D who underwent MWA and were divided into training (n=149) and validation (n=37) cohorts. Preoperative clinical parameters and portal-venous phase MRI radiomic features were extracted. A radiomics score (RAD -score) was constructed using the K-nearest neighbors (KNN) algorithm after feature selection. A clinical model was built using logistic regression, and a nomogram integrating clinical factors and the RAD -score was established. Model performance was evaluated using ROC curves, calibration curves, and decision curve analysis (DCA). Kaplan--Meier curves, pathological analysis, and immunohistochemistry validated prognostic stratification. Results: Four core radiomic features were identified. The combined nomogram achieved AUCs of 0.877 (training) and 0.846 (validation), outperforming the clinical (AUC 0.718) and radiomics (AUC 0.774) models alone. In the validation cohort, the sensitivity, specificity, and negative predictive value were 80.0%, 83.8%, and 90.1%, respectively. DCA showed a significant net benefit across threshold probabilities of 0.1-0.9. High-risk patients had a 5.8-fold (training) and 2.51-fold (validation) higher recurrence risk with significantly shorter progression-free survival. Pathological and immunohistochemical analyses confirmed more aggressive tumor features (higher rates of microvascular invasion, poor differentiation, thick-trabecular type, CD34 expression, and glypican-3 expression) in the high-risk group. Conclusion: The nomogram provides a satisfactory prediction of early recurrence within two years after MWA in HCC patients with T2D, enabling individualized postoperative surveillance and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.